Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages
    Reference: 20210078
    Release date: 18 March 2022

    Promoter – Financial Intermediary

    STILLA TECHNOLOGIES SAS

    Location

    Description

    The project focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution in a Paris-based European biotechnology company. 

    Additionality and Impact

    The project addresses the failure in financial markets for small innovative and high-growth companies arising from the limited access and/or prohibitive cost of financing charged by creditors/investors as a result from information asymmetries, higher uncertainty, lack of collateral and imperfect screening and monitoring. The project is in line with the objectives of Horizon Europe program.

    The project will deliver an improved platform for digital PCR which has a broad application in life science research and molecular diagnostics. Applications can be found in liquid biopsies, infectious diseases, absolute quantification needed in testing such DNA methylation, viral titering, and disease-related gene amplifications, among others.

    EIBs financing would be complementary to European VC investors and would provide a signalling effect to crowd-in other capital providers, which are necessary for the completion of the product development stage and commencing commercial operations.

    Objectives

    The proposed transaction will support research and development (R&D) investments that are required in order to advance the development of the next generation of the Promoter's digital PCR (dPCR) platform and expand the range of tests available. By co-investing in the project, the Bank contributes to improving healthcare, whilst also fostering the generation of European scientific knowledge and acumen, preserving and cultivating highly skilled employment opportunities.

    Comments

    Stilla Technologies is a a French medtech company focused on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible dPCR solution: the naica® system ("Naica"). Since its incorporation in 2013, the company has developed the dPCR platform "Naica," commercially available in research laboratories since 2016 and used by researchers around the world in a wide range of genetic tests and molecular biology assays.

    Sector(s)

    • Services - Professional, scientific and technical activities

    Proposed EIB finance (Approximate amount)

    EUR 20 million

    Total cost (Approximate amount)

    EUR 44 million

    Environmental aspects

    The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

    Procurement

    The Promoter is a private company not operating in the utilities sector and not having the status of a contracting authority; thus, the project is not covered by the EU Directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

    Status

    Signed - 4/11/2021

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Related tags

    France Services